|
|
|||
|
||||
OverviewClassic psychedelics such as psilocybin, LSD, ayahuasca, 5-MeO-DMT, and mescaline are multifaceted substances that have been used for healing and ritual purposes for millennia. In recent years, scientific interest in their therapeutic potential has resurged, yielding promising results for the treatment of mental health conditions, including depression, anxiety, and substance use disorders. At the same time, growing public interest and enthusiastic media coverage have contributed to increasing use in non-clinical contexts. Although psychedelics are considered not addictive and exhibit very low toxicity, their use can, in some cases, be associated with considerable risks and complications. To date, these risks remain underresearched, and many mental health professionals are insufficiently informed about their pathophysiology, differential diagnosis and clinical management. This book seeks to address this gap. From an interdisciplinary perspective, it aims to contribute to a more nuanced and balanced understanding of the benefit–risk ratio and to offer practical guidance for managing complications that may arise when psychedelics are used in therapy and beyond. The chapter ""Classifying Psychedelic-Related Complications"" is available open access under the Creative Commons Attribution Non Commercial - No Derivatives 4.0 International License via link.springer.com. Full Product DetailsAuthor: Tomislav MajićPublisher: Springer Nature Switzerland AG Imprint: Springer Nature Switzerland AG ISBN: 9783032211064ISBN 10: 3032211069 Pages: 567 Publication Date: 05 May 2026 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Not yet available This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release. Table of ContentsReviewsAuthor InformationDr. med. Tomislav Majić: Licensed psychiatrist and psychotherapist in Berlin, Germany, with a focus on psychosis, substance use, double diagnosis and harm reduction. Studied medicine at Charité University Clinic Berlin until 2005. Co-founder and lead of „Psychedelic Substances Research Group"" at Charité. Lecturer and supervisor for psychodynamic therapy at Berlin Institute for Psychotherapy and Psychoanalysis (BIPP). Founder of day clinic for patients with double diagnoses (2017) and outpatient treatment for patients suffering from psychedelic-related disorders (2017) (""Ambulanz Psychedelische Substanzen"") at Psychiatric University Clinic of Charité at Hospital St. Hedwig Berlin. Study therapist and researcher investigating therapeutic effects of classic psychedelics as well as psychedelic-related complications Tab Content 6Author Website:Countries AvailableAll regions |
||||